Analysis of nuclear factor kappa B (NF-κb) associated non-coding rnas (ncRNA) in patients with psoriasis vulgaris

Psoriasis is a common chronic inflammatory skin disease associated with multiple comorbidities in which genetic, environmental and immunologic factors play a combined role. Pathogenesis of psoriasis is multifactorial. Especially in early-onset psoriasis, genetic factors are very important in the pathogenesis. Recent studies focus on the roles of non-coding RNAs (ncRNA) in pathogenesis. Non-coding RNAs are RNA transcripts that are actively transcribed in the genome but do not code for proteins. Long noncoding RNAs (lncRNA) are regulatory noncoding RNAs longer than 200 nucleotides. Long non-coding RNAs have been associated with many diseases, especially cancers. There are also many long noncoding RNAs associated with psoriasis. Non-coding RNAs regulate the activities of signaling pathways such as nuclear factor kappa B (NF-κB), JAK-STAT, mTOR, and MAPK. Nuclear factor kappa B is one of the important signaling pathways in the pathogenesis of psoriasis. In our study, we analyzed the expressions of lncRNA PACER and H19, which are long noncoding RNAs associated with NF-kB, in psoriasis patients. We also analyzed the mRNA expression of COX-2 and p65, which are the targets of these genes, and additional p50. For our study, biopsies were taken from the lesional skin of 35 patients with psoriasis vulgaris (17 males, 18 females) who did not use systemic therapy, phototherapy in the last 3 months, and topical therapy in the last 1 month. In the control group, waste tissues of patients operated on in plastic surgery or patients who underwent blepharoplasty were used. 32 healthy controls (20 female, 12 male) without dermatological disease were included in the study. PACER and H19 expressions were found to be increased in psoriasis patients compared to healthy controls. COX-2, p65 and p50 expressions were found to be decreased in psoriasis patients compared to healthy controls. PACER and H19 expression change rates increased more in male patients compared to females. PACER and H19 expression change rates increased more in early-onset psoriasis patients compared to late-onset psoriasis patients. PACER expression change rates increased more in patients with mild psoriasis compared to patients with moderate/severe psoriasis. COX-2 expression change rates decreased more in psoriasis patients without family history compared to psoriasis patients with family history. Positive correlations were found between PACER and H19, COX-2 and p65, p65 and p50 in both patient and control groups. In the control group, a positive correlation was found between COX-2 and p50. In the patient group, negative correlations were found between PACER and the age of the patients, between PACER and the body mass index of the patients. In the patient group, there was a positive correlation between the age of the patients and their body mass index. The data obtained from this study will provide us with new information on the pathogenesis and genetics of psoriasis. With the new data we have obtained, we aim to contribute to the development of new personalized treatment strategies in the future.